8-K filing — BioStem Technologies, Inc. (BSEM)
Filed: 2026-08-12 AccNo: 0001193125-26-347211 Size: 459 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
BioStem Technologies shares are trading lower after the company reported a year-over-year decrease in Q2 sales results.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 4:19 PM
- Checked
- Aug 13, 2026, 4:19 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY
BioStem Technologies (NASDAQ:BSEM) reported quarterly losses of $(0.52) per share. The company reported $7.899 million in sales this quarter. This is a 27.95 percent decrease over sales of $10.963 million the same
Read original at benzingaBioStem Technologies Announces Nasdaq Uplisting
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced that Nasdaq has approved its common stock for listing on The Nasdaq Capital Market. Trading under ticker symbol 'BSEM' is expected to begin on August 7, 2026. The uplisting is expected to expand the company's access to capital, improve market visibility and liquidity, and enhance its ability to attract talent.
Read original at globenewswire-inc